

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 April 2002 (25.04.2002)

PCT

(10) International Publication Number
WO 02/33402 A2

(51) International Patent Classification⁷: G01N 33/00

(21) International Application Number: PCT/EP01/12337

(22) International Filing Date: 22 October 2001 (22.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/241,836 20 October 2000 (20.10.2000) US

(71) Applicant (for all designated States except US): **VIRCO**
N.V. [BE/BE]; Generaal De Wittelaan L11B4, B-2800
Mechelen (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HERTOGS, Kurt**
[BE/BE]; Quinten Matsijlslei 11/42, B-2018 Antwer-
pen (BE). **LARDER, Brendan** [GB/GB]; Monona 6,
Churchlane, Cambridge, Cambridgeshire CB3 7HQ (GB).
HARRIGAN, Richard, P. [CA/CA]; c/o British Columbia
Center for Excellence in HIV/AIDS, 613-1081 Burrard
St., Vancouver, British Columbia V6Z 1Y6 (CA).

(74) Agent: **DAELEMANS, Frank**; Tibotec-Virco N.V.,
Intellectual Property Department, Generaal De Wittelaan
L11B3, B-2800 Mechelen (BE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ESTABLISHMENT OF BIOLOGICAL CUT-OFF VALUES FOR PREDICTING RESISTANCE TO THERAPY

(57) Abstract: The present invention concerns methods and systems for improving the accuracy of predicting resistance of a disease to a therapy. In one embodiment of the invention, mean and standard deviation (SD) values of fold change in normalized sensitivity, relative to a laboratory wild type standard pathogen or malignant cell are calculated to demonstrate that the patient samples display inherently different degrees of variation in susceptibility to each therapy. In another embodiment, the 2xSD value for each therapy is used as the cut-off between sensitive (within normal susceptible range) and resistant (above normal susceptible range).

WO 02/33402 A2

ESTABLISHMENT OF BIOLOGICAL CUT-OFF VALUES FOR PREDICTING RESISTANCE TO THERAPY

The present invention concerns methods and systems for improving the
5 accuracy of predicting resistance of a disease to a therapy. More specifically, the
invention provides methods for establishing the natural phenotypic variability in
therapy resistance among individuals for available therapies which serve to establish
biological cut-off values for phenotypic or genotypic resistance tests. The invention
may be used in concert with any test or assay used to determine the phenotype or
10 genotype of a disease. For example, the invention may be applied to tests that
determine the resistance of a virus isolate to various antiviral drugs. The invention also
relates to methods and systems for improving the accuracy of predicting a disease's
clinical response to a particular therapy or combination of therapies.

As used herein, the term "disease" refers to a pathogen or malignant cell that
15 causes a pathological condition in an organism from the pathogen's infection or
malignant cell's replication. The term "pathogen", as used herein, includes but is not
limited to bacteria, viruses such as human immunodeficiency virus (HIV), hepatitis C
(HCV) or hepatitis B (HBV), prions, algae, fungi and protozoa. The term "malignant
cells", as used herein, includes but is not limited to cells with malignant characteristics,
20 growth transformed cells, cells that continue to grow past the point of contact
inhibition, cells that divide with abnormally high frequency as compared to normal
cells of the same type or cells that exhibit anaplasia, invasion and metastasis. A
therapy, as used herein, refers to any animal, vegetable, mineral, pharmaceutical
substance, form of radiation, or gene therapy used to treat a pathogen or malignant cell.
25 It is understood that the term "active ingredient" refers to chemicals, drugs, thereof
compounds, peptides, proteins, antibodies, aptamers, DNAs (including anti-sense
DNA), RNAs, ribozymes and pharmaceutical acceptable compositions. A "patient
sample" is defined as any sample obtained from an individual such as blood, serum
plasma. Of this sample the pathogen may be used or proteins, or nucleic acids derived
30 from said pathogen. A "reference sample" is defined as a standard laboratory reference
pathogen such as for example the HIV LAI IIIB strain. "Susceptibility" or "sensitivity"
to a therapy refers to the capacity of the disease, malignant cell, and/or pathogen to be
affected by the therapy. "Resistance" refers to the degree to which the disease,
malignant cell, and/or pathogen is unaffected by the therapy. The sensitivity,
35 susceptibility or resistance of a disease towards a therapy may be expressed by means
of an IC_{50} value. The IC_{50} value is the concentration at which a given therapy results in
a reduction of the pathogen's growth compared to the growth of the pathogen in the
absence of a therapy. Resistance of a disease to a therapy may be caused by alterations

in phenotype or genotype. Genotypic alterations include mutations, single nucleotide polymorphisms, microsatellite variations, epigenetic variations such as methylation. Phenotypic variations may be effected by genotypic variations or by post-translational modification.

5 Techniques to determine the resistance of a disease to a therapy are becoming increasingly important. Since the issuance of the first report suggesting a correlation between the emergence of viral resistance and clinical progression, techniques to determine the resistance of a pathogen or malignant cell to a therapy have been increasingly incorporated into clinical studies of therapeutic regimens. Brendan Larder
10 *et al.*, HIV Resistance and Implications for Therapy (1998), herein incorporated by reference. For example, as with viral infections, some studies also show that p53 mutations may also be predictive of tumor response to specific anticancer drug therapy, radiation treatment or gene therapy. This is the case in breast cancer where initial studies have shown that cisplatin and tamoxifen® are more effective in patients whose
15 tumors have a p53 mutation. Thus, the aim of resistance monitoring is to provide the necessary information to enable the physician to prescribe the most optimal combination of therapies for the individual patient.

With more therapeutic options becoming available, phenotypic therapy resistance testing is expected to play an important role in the management and
20 treatment of pathogen infection or cancer and the development of individualized treatment regimes [see e.g. Haulbrich et al. JAIDS, 2001, 26S1, S51-S59.]. Furthermore, the number of drug resistant diseases also increases. Phenotyping methodologies measure the ability of a pathogen or malignant cell to grow in the presence of different therapy(s) in the laboratory. This is usually expressed as the fold-
25 change in the IC₅₀ or IC₉₀ values (the IC₅₀ or IC₉₀ value being the therapy concentration at which 50% or 90% respectively of the population malignant cells is inhibited from replicating). A highly resistant malignant cell might show a 50 or 100-fold increase in IC₅₀, for example. Some mutations only increase the IC₅₀ by as little as 2-3 fold. Unlike genotyping, phenotyping is a direct measure of susceptibility, reflecting the
30 effects and interactions of all the mutations, known or unknown, on the behavior of the malignant cell population in the presence of therapy(s). On the other hand the cut-of value may be used to indicate hypersensitivity of a pathogen towards a given therapy. It has been demonstrated that a combination of HIV mutations lead to hypersensitivity of the pathogen towards a given therapy.

35

Although phenotyping is considered the 'gold standard' of resistance testing, its utility is dependent on the "cut-off" value of the fold increase in for example the IC₅₀ at which a pathogen or malignant cell is considered resistant. The term "cut-off value", as

used herein, refers to the change in susceptibility above which the pathogen or malignant cell is classed as having reduced susceptibility for a particular therapy. "Therapy resistance," as used herein, pertains to the capacity of resistance, sensitivity, susceptibility or effectiveness of the therapy against the pathogen or malignant cell.

5 There has been recent debate regarding the relevance of cut-off values currently in use. For example, currently used virological cut-off values, are usually the same value for each therapy tested and are determined not by clinical criteria but, for example, by the assay variability seen on repetitive testing of a single wild type (wt) standard virus. Some virological cut-off values are clearly out of line with known response data. For
10 example, indications of low level resistance to non-nucleotide reverse transcriptase inhibitors (NNRTIs) does not lead to blunted responses to therapy in previously untreated individuals (Harrigan et al, Bachelor et al., 4th International Workshop on HIV Drug Resistance and Treatment Strategies, Sitges, Spain. Abstr. (2000).) Other
15 assays have cut-off values that are primarily based on the reproducibility of the assay, are the same for each therapy, or are not related to whether a therapy might work against the pathogen or malignant cell in clinical practice and are, therefore, rather arbitrary.

Summary and Detailed Description of the Invention

20

A solution to these problems of "cut-off" values involves new methods for establishing the natural phenotypic variability in therapy resistance among untreated individuals for available therapies, serving to generate biologically relevant cut-off values for a phenotypic resistance test. The resulting, newly defined cut-off values,
25 herein termed biological cut-off values, are a more accurate reflection of natural variation in the population and may prove to be more predictive of clinical response than virological cut-off values.

In one embodiment of the invention, biological cut-off values are determined from the mean and standard deviation (SD) values of fold change in sensitivity, also
30 termed "fold resistance" herein, of patient samples relative to a laboratory wild type standard pathogen or malignant cell reference sample, which are calculated to demonstrate that the patient samples display inherently different degrees of variation in susceptibility to each therapy after raw data is normalized (e.g., log transformed). The mean and standard deviation may be calculated from any of the methods known to
35 those of skill in the art.

In one embodiment the instant invention concerns a method for predicting resistance of a disease to at least one therapy, comprising:

- a) determining the sensitivity of a patient sample for said at least one therapy;

- b) determining the sensitivity of a reference sample for said at least one therapy;
 - c) determining the patient fold resistance from the quotient of the sensitivity obtained in step a) over the sensitivity obtained in b);
 - d) predicting resistance of a disease toward the at least one therapy by
- 5 determining whether the patient fold resistance is above a cut-off fold resistance value,
- wherein the cut-off fold resistance value is determined from the mean and standard deviation of a distribution of patient fold resistance values for the at least one therapy determined for a group of patients

10

According to the instant invention a group of patients useful to establish the distribution of fold resistances is 10 to 50 patients. Preferably a group of 50 to 500 patients may be used to determine the distribution of the fold resistances. More preferably a population

15 of at least 500 patients is used to determine the distribution of the fold resistances. The distribution can be a normal distribution (Gaussian distribution) or can be a non-normal distribution. The non-normal distribution may be transformed to obtained a normal distribution.

In some embodiments, the patient samples are treatment naïve. The treatment

20 naïve samples may also include pathogenic material, such as genetic material, that is predicted to be wild-type, or that is classed as wild-type by those in the art on the basis of its known sequence.

In some embodiments, at least about the mean fold increase in sensitivity + 2xSD value for each therapy is used as the cut-off between sensitive (within normal

25 range) and resistant (above normal range) after raw data is normalized. Thus, in some embodiments, the 2xSD value, which is equivalent to the 95% upper confidence limit on a Gaussian distribution, may be used as the cut-off fold resistance value. (See Fig. 1). In this latter case 97.5% of the increases in fold resistance will be below this 95% upper confidence interval. In other embodiments, a higher confidence limit, such as the

30 97.5% upper confidence limit may be used as the cut-off value.

In some embodiments of the invention, the method may be used to determine the fold resistance for several, or all, available therapies for a disease.

The invention may be used with any of the diseases and therapies provided in the above definitions. For example, it may be used to predict resistance to one or more

35 therapies to a pathological condition caused at least in part by a pathogenic infection or malignant cell replication.

Essential in therapy monitoring is deciding whether therapy is still effective. This decision relies on comparing the drug effect at the patient borne target with a

reference target. This comparison provides a quotient of the effect at the patient target over the reference. Often this is expressed as a fold increase in resistance, wherein resistance can be expressed by means of an IC_{50} value. The IC_{50} can be the concentration at which the drug reduces the activity of the target by half compared to the activity of the target without inhibitor. The decision whether a compound or a drug is still effective resides in the cut-off i.e. a defined increase in IC_{50} . This cut-off is often based on the variability of the assay. This provides a cut-off that depends largely on the analytical performance of the assay. This approach suffers from the limitation that it does not consider the population based variation in drug responsiveness. In addition, such approach does not account for the different responsiveness towards different therapy regimens.

Since the current approaches do not account for the population based variability in resistance sensitivity, we determined the mean fold change in IC_{50} in a mixed population of untreated patients to provide a biological distribution of the fold changes in IC_{50} . A mixed population is not restricted to e.g. a single gender, age, race, sexual behavior. Secondly, the method of the instant invention accounts for the different responsiveness in a population towards different drugs. Therefore the drug specific cut-off values determined by the instant approach, are more reliable parameters in estimating resistant over sensitive patients. In a further approach, the population based mean fold increase in cut-off was determined in patients bearing a wild type sequence. This further refinement accounts for potential bias in the fold increase in resistance due to potential treatment resistant individual in the population evaluated. Unexpectedly, the results from both approaches i.e. phenotyping in treatment naïve patients and virtual phenotyping in a population under treatment but still having a wild type pathogen, yielded similar mean fold changes in resistance for each evaluated HIV drug.

Any method capable of measuring changes in the ability of a pathogen or malignant cell to grow in the presence of a therapy(s) can be used in the present invention. Such methods of phenotyping include all methods known to persons of skill in the art. Known genotyping methods may also be used in the present invention.

For example and by way of illustration, methods for phenotyping bacteria suitable for use in the present invention include, but are not limited to, measurement of inhibitory zone diameters (see, e.g., Guoming *et al.*, *Sex. Transm. Dis.* 27(2):115-8 (2000), expressly incorporated herein by reference), colorimetric indicator methods (see, e.g., Lozano-Chiu *et al.*, *Diagn. Microbiol. Infect. Dis.* 31(3):417-24 (1998), expressly incorporated herein by reference), and broth macrodilution method (see, e.g., Iwen *et al.*, *J. Clin. Microbiol.* 34(7):1779-83 (1996), expressly incorporated herein by reference).

As an additional illustrative example, methods for phenotyping viruses suitable for use in the present invention include, but are not limited to, plaque reduction assays, PBMC p24 growth inhibition assays (see, e.g., Japour *et al.*, *Antimicrob. Agents Chemother.* 37:1095-1101 (1993); Kusumi *et al.*, *J. Virol.* 66:875-885 (1992), both of which are expressly incorporated herein by reference), recombinant virus assays (see, e.g., Kellam & Larder, *Antimicrob. Agents Chemother.* 38:23-30 (1994); and Pauwels *et al.*, 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy. Abstr. 51(1998), all of which are expressly incorporated herein by reference); the use of GFP as a marker to assess the susceptibility of anti-viral inhibitors (Marschall *et al.*, Institute of Clin. and Mol. Virol., University of Erlanger-Nuremberg, Schlobgarten, Germany); and cell culture assays (Hayden *et al.*, *N. Eng. J. Med.* 321:1696-702 (1989), herein incorporated by reference).

As yet another illustrative example and by way of illustration, methods for phenotyping malignant cells suitable for use in the present invention include, but are not limited to, flow cytometric assays (see, e.g., Pallis *et al.*, *Br. J. Haematol.* 104(2):307-12 (1999); Huet *et al.*, *Cytometry* 34(6):248-56 (1998), both of which are expressly incorporated herein by reference), fluorescence microscopy (see, e.g., Nelson *et al.*, *Cancer Chemother. Pharmacol.* 42(4):292-9 (1998), expressly incorporated herein by reference), calcein accumulation method (see, e.g., Homolya *et al.*, *Br. J. Cancer.* 73(7):849-55 (1996), expressly herein incorporated by reference), and ATP luminescence assay (see, e.g., Andreotti *et al.*, *Cancer Res.* 55(22):5276-82 (1995), expressly incorporated herein by reference).

Though the invention may be used with any phenotype or genotype measuring test or assay that determines resistance, the following descriptions are designed to further describe possible applications of the invention.

In one embodiment, the biological cut-off values may be used in concert with direct phenotype assays, for example, AntivirogramTM (Virco, Inc.; WO 97/27480, US 6,221,578 incorporated herein by reference). This assay is a phenotypic resistance assay that measures, in controlled laboratory conditions, the level of resistance of the HIV derived from an individual patient to each of the anti-HIV therapies currently available. The resistant 'behavior' of the virus may be the combined result of the effects of many different mutations and the complex interactions between them, including genetic changes that have not even been identified yet. In other words, it is a direct measure of resistance.

The test provides a quantitative measure of viral resistance to all the available drugs. This is expressed in terms of the IC₅₀. This is then compared to the IC₅₀ for fully sensitive, non-mutated 'wild-type' virus. The resistance of the sampled virus to each therapy is then expressed in terms of a fold-change in IC₅₀ compared to wild type.

The report enables physicians to identify the therapy(s) that are no longer active and helps in the selection of the optimal combination of drugs for the individual patient.

5 In one embodiment of the invention, the degree of resistance of thousands of samples from untreated patients is measured, as well as of genetically wild-type viruses (viruses without any resistance mutations). The average susceptibility of the viruses tested vary from drug to drug. A unique cut-off value for each therapy based on these biological data may be set, so that a result above the cut-off values means that the virus can be said to be above the normal sensitive range with a high degree of confidence. For example, in one embodiment the level of confidence may be 97.5%.

10 In another embodiment, the invention may also be used in concert with rules-based or other less direct systems of determining the therapy resistance phenotype of a pathogen or malignant cell. An example of a less direct system is the Virtual Phenotype™ (Virco, Inc.; PCT/EP01/04445, incorporated herein by reference). This system predicts viral therapy resistance based on genotypic information. For example
15 the reverse transcriptase or protease genes of a virus e.g. HIV are sequenced and compared to wild type sequence to identify mutations in these genes.

The genetic code for the region involved in drug resistance is fed into a software system. This system identifies all the mutations that can affect resistance to each drug. It then interrogates a database of genotypes and phenotypes to find
20 genotypes from previous samples that match these mutations. When all the matches have been identified, the software retrieves the phenotypes for these samples and produces a VirtualPhenotype™ by calculating the average increase in resistance for each drug. The VirtualPhenotype™ is typically based on data from hundreds or thousands of real phenotypes with the same patterns of mutations. In this example, an
25 increase in the accuracy by which a virus' therapy resistance is determined, by use of biologically relevant cut-off values, translates into an increase in the accuracy of predicting a virtual phenotype for a new virus isolate based on its genotype. Finally, the cut-off values of this indirect system can be chosen to improve the specificity and/or sensitivity of the indirect system at predicting whether or not a sample is above
30 or below the biologically relevant cut-off values

In yet another embodiment, the invention may also be used in concert with other systems for determining phenotype from genotype information, such as neural networks that determine the therapy resistance phenotype of a pathogen or malignant cell based on its genotypic information.

35 For example, a neural network may be used to model the relationship between genotype and phenotype for therapy resistance testing (U.S. Patent Application No. 09/589,167, PCT/EP01/06360 incorporated herein by reference). The neural network may be used to identify mutation(s) or mutation patterns that confer resistance to a

therapy and defines the genetic basis of therapy resistance. For example, a data set of genotypic and phenotypic data is collected from a phenotype-genotype database. Each member of the data set corresponds to a genetic mutation that is correlated to a phenotypic change in therapy resistance.

5 The data set is divided into a training data set and a testing data set. After the network has been trained, the prediction rate or concordance rate of the network is determined from a test data set. Samples which give an incorrect prediction are removed from the test data set and placed into a second training data set. The second training data set comprises the first data training set plus any samples that gave an
10 incorrect prediction from the test data set. The second training data set is then used to re-train the neural network. If necessary, this process can be repeated until the desired performance level is achieved. By re-training the neural network in this fashion, it is possible to increase the performance of the neural network. The accuracy of this application, because it relies on a database of genotype and phenotype information, is
15 enhanced by improvements on determining phenotypic therapy resistance with the use of the present invention's biological cut-off values.

 In one embodiment the instant invention concerns a diagnostic tool for determining the resistance of a patient to at least one HIV therapy comprising the cut-off fold resistance value for said at least one therapy as determined herein. The
20 diagnostic tool includes phenotypic resistance tests such as the Antivirogram®, VirtualPhenotyping®, Phenosense.

 The instant invention concerns methods to determine resistance towards HIV compounds such as tenofovir, lopinavir, and those compounds disclosed in WO 99/67417, EP-A-945443 and WO 00/27825. In particular, [3R-[3 α (1S*,2R*),3 α
25 β ,6 $\alpha\beta$]]-[3-[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl] carbamic acid hexahydrofuro[2,3-b]furan-3-yl ester or 4-[[6-amino-5-bromo-2-[(4cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl benzonitrile or 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino benzonitrile or any pharmaceutically acceptable salt or any stereoisomeric from thereof.

30 In one embodiment the effect of drugs on HBV may be monitored using technologies such as disclosed by Isom et al. (WO 99/37821, Delaney et al. Antimicrob. Agents chemotherap. 2001, 45(6) 1705-1713).

 In one embodiment the effect of drugs on HCV towards therapy may be determined using techniques such as described by Rice (WO 97/08310, WO 98/39031)
35 and Barthenschlager (EP 1043399) .

Brief Description of the Figures

Fig. 1: Example curve showing the mean and 2x standard deviation of the fold change in drug sensitivity of a diverse set of patient samples for a given therapy.

Fig. 2: The mean fold resistance (Mean FR) of patient samples to a variety of available anti-viral drugs. Data are calculated from both direct phenotyping of drug naïve patients (PT) and virtual phenotyping of patients with wild type-like virus currently taking drugs (vPT). N refers to the number of patient samples tested. The anti-viral drugs used are AZT, ddI, ddC, d4T, abacavir (ABC), nevirapine (NVP), delavirdine (DLV), efavirenz (EFV), indinavir (IDV), ritonavir (RTV), nelfinavir (NFV), saquinavir (SQV), and amprenavir (APV).

Fig. 3: Mean fold resistance (Mean FR) for patient samples compared with the 2x standard deviation (2SD) range. The dashed line at 4-fold increase in sensitivity is the previously used phenotypic cut-off value.

Fig. 4: Comparison of old and new phenotypic cut-off values for anti-viral drugs.

Fig. 5: Effect of the new cut-off values on the prediction of resistance to anti-viral drugs.

Fig. 6: Predicted resistance to anti-viral drugs predicted from phenotype (PT) and virtual phenotype (vPT) testing in 5000 samples without known drug resistance mutations using old cut-off values.

Fig. 7: Predicted resistance to anti-viral drugs predicted from phenotype (PT) and virtual phenotype (vPT) testing in 5000 samples without known drug resistance mutations using new cut-off values.

The following example is provided by way of illustration and is not intended to be limiting of the present invention.

Example 1

Determination of Biologically Relevant Cut-Off values for different Anti-HIV Therapies.

Drug susceptibility of approximately 1000 geographically diverse untreated patient samples was determined for all currently approved antiretrovirals using the Antivirogram™ assay. Mean and standard deviation (SD) values of the fold change in sensitivity (log scale) of the patient samples relative to a laboratory wild type standard virus, demonstrated that the patient samples displayed inherently different degrees of variation in susceptibility to each drug (smallest variation with protease inhibitors (PIs)

and greatest with the NNRTIs). The fold change in sensitivity of the samples to a drug is also termed the fold resistance of the samples to the drug. The 2xSD value for each drug was used as the cut-off between sensitive (within normal susceptible range) and resistant (above normal susceptible range). Given this cut-off value, 97.5% of samples fall within a normal susceptible range while 2.5% were above normal range, indicating that untreated individuals will usually fall into the sensitive range. Figure 1 represents an example of such an analysis for a single antiviral drug. These varied between 3-4.5 fold for the nucleosides, 6-10 fold for the NNRTIs and 2.5-4 fold for the PIs.

For cross validation, the mean fold resistance values for a large group of genotypically "wild type" samples were calculated (between 2100-7500 per drug). These values coincided almost exactly with the mean values derived from the untreated patient samples. Thus, the newly defined biological cut-offs were an accurate reflection of natural variation in the population and proved to be more predictive of clinical response than existing cut-off values. Figure 2 contains the mean fold resistance values for several samples, employing both direct phenotyping (PT group) and virtual phenotyping methods (vPT group). A fold resistance of approximately one means that there is no difference with the wild type laboratory virus, thus the person is susceptible to therapy. The PT group represents drug naïve patients while the vPT group represents individuals who already take drugs but do not display mutations known to confer significant resistance upon genotyping (e.g. they resemble drug naïve patients).

Figure 3 demonstrates the mean fold resistance (light gray) found for the number of samples indicated at the bottom in the context of the 2 x SD range (dark gray background). Several drugs differed from the arbitrarily chosen 4 fold increase in sensitivity, which was the phenotypic cut-off previously employed for this assay

Although the relationship of the new cut-off values to clinical response is still under investigation, it was already apparent that modest increases in resistance to NNRTIs (around 2.5-5 fold) did not predict treatment failure. Figure 4 contains a comparison of the old and new cut-off values. Worthy of note is the observation that delavirdine (DLV) shows an increase from 4 to 10, but this increase did not actually affect the decision of many samples. On the contrary, d4T, which showed a decrease in cut-off value resulted in a doubling of the number of resistant sample (see also Figure 5). Figure 5 shows the effect of the change in cut-off value (shown in Figure 4) on the decision taken concerning resistance of the samples.

Figure 6 shows the resistance called by both phenotype and virtual phenotype testing in 5000 samples without known drug resistance mutations. . When compared with Figure 6, Figure 7 demonstrates that the new biological cut-off values yield a better concordance between virtual phenotyping and direct phenotyping.

All patents, patent applications and references referred to are incorporated herein by reference in their entirety.

Claims

1. A method for predicting resistance of a disease to at least one therapy, comprising:
 - a) determining the sensitivity of a patient sample for said at least one therapy;
 - b) determining the sensitivity of a reference sample for said at least one therapy;
 - c) determining the patient fold resistance from the quotient of the sensitivity obtained in step a) over the sensitivity obtained in b);
 - d) predicting resistance of a disease toward the at least one therapy by determining whether the patient fold resistance is above a cut-off fold resistance value,
wherein the cut-off fold resistance value is determined from the mean and standard deviation of a distribution of patient fold resistance values for the at least one therapy determined for a group of patient
2. The method of claim 1, wherein said patient samples are treatment naïve.
3. The method of claim 1, wherein the treatment naïve patient samples comprise pathogenic material, wherein the pathogen is predicted to be genotypically wild-type.
4. The method of claim 1, wherein the sensitivity is expressed by an IC_{50} value.
5. The method of claim 1, wherein the cut-off fold resistance value is determined as the mean plus two times the standard deviation of the distribution of patient fold resistance values.
6. The method of claim 1, wherein the disease is caused at least in part by infection with a pathogen.
7. The method of claim 6, wherein the pathogen is at least one of bacteria, viruses, prions, fungi, algae, and protozoa.
8. The method of claim 7, wherein the pathogen is a bacteria.
9. The method of claim 7, wherein the pathogen is a virus.

10. The method of claim 9, wherein the virus is selected from human immunodeficiency syndrome, Hepatitis C, Hepatitis B
- 5 11. The method of claim 1, wherein the disease is caused at least in part by replication of malignant cells.
12. The method of claim 1, wherein the sensitivity of the patient sample is determined by at least one of a phenotyping assay and a genotyping assay.
- 10 13. The method of claim 12, wherein the phenotyping assay includes at least one of measurement of inhibitory zone diameters, colorimetric indicator methods, and broth macrodilution.
- 15 14. The method of claim 12, wherein the phenotyping assay includes at least one of plaque reduction assays, peripheral blood mononuclear cell p24 growth inhibition assays, recombinant virus assays, green fluorescent protein marker assays, and cell culture assays.
- 20 15. The method of claim 12, wherein the phenotyping assay includes at least one of flow cytometry, fluorescence microscopy, calcein accumulation, and ATP luminescence.
- 25 16. The method of claim 1, wherein the resistance of the patient sample is determined by a neural network.
17. The method of claim 1, wherein the therapy is antiviral therapy.
18. The method of claim 17, wherein the therapy comprises protease inhibitor therapy.
- 30 19. The method of claim 17, wherein the therapy comprises reverse-transcriptase inhibitor therapy.
20. The method of claim 17, wherein the reverse-transcriptase inhibitor therapy comprises non-nucleoside reverse-transcriptase inhibitor therapy.
- 35

21. The method of claim 17, wherein the therapy includes treatment with at least one of AZT, ddI, ddC, d4T, abacavir, nevirapine, delavirdine, efavirenz, indinavir, ritonavir, nelfinavir, saquinavir, amprenavir, lopinavir, tenofovir.
- 5 22. The method of claim 17, wherein the therapy comprises at least one of envelope inhibitor, fusion and integrase inhibitor treatment.
23. A diagnostic tool for determining the resistance of a patient to at least one HIV therapy comprising the cut-off fold resistance value for said at least one therapy as
10 determined according to the method of claim 1.




FIGURE 1




FIGURE 2




FIGURE 3

DRUG	Previous Cut Off	New Cut Off
AZT	4.0	4.0
3TC	4.0	4.5
ddI	4.0	3.5
ddC	4.0	3.5
d4T	4.0	3.0
ABC	4.0	3.0
NVP	4.0	8.0
DLV	4.0	10.0
EFV	4.0	6.0
IDV	4.0	3.0
RTV	4.0	3.5
NFV	4.0	4.0
SQV	4.0	2.5
APV	4.0	2.5

FIGURE 4

DRUG	Previous Cut Off (% Res)	New Cut Off (% Res)	Change (%)	Relative change
AZT	33.5	33.5	0.0	0
3TC	47.3	46.0	-1.3	-3
ddI	8.8	11.9	3.0	35
ddC	6.5	8.5	2.0	31
d4T	7.1	12.5	5.4	77
ABC	18.4	25.8	7.4	40
NVP	42.4	36.3	-6.2	-15
DLV	43.7	31.2	-12.5	-29
EFV	32.9	29.8	-3.1	-10
IDV	27.0	29.6	2.6	10
RTV	32.4	33.3	0.9	3
NFV	37.0	37.0	0.0	0
SQV	22.0	25.1	3.1	14
APV	12.6	19.3	6.8	54

FIGURE 5




FIGURE 6




FIGURE 7

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 April 2002 (25.04.2002)

PCT

(10) International Publication Number
WO 02/33402 A3

(51) International Patent Classification⁷: G01N 33/50

(21) International Application Number: PCT/EP01/12337

(22) International Filing Date: 22 October 2001 (22.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/241,836 20 October 2000 (20.10.2000) US

(71) Applicant (for all designated States except US): **VIRCO**
N.V. [BE/BE]; Generaal De Wittelaan L11B4, B-2800
Mechelen (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HERTOGS, Kurt**
[BE/BE]; Quinten Matsijlslei 11/42, B-2018 Antwer-
pen (BE). **LARDER, Brendan** [GB/GB]; Monona 6,
Churchlane, Cambridge, Cambridgeshire CB3 7HQ (GB).
HARRIGAN, Richard, P. [CA/CA]; c/o British Columbia
Center for Excellence in HIV/AIDS, 613-1081 Burrard
St., Vancouver, British Columbia V6Z 1Y6 (CA).

(74) Agent: **DAELEMANS, Frank**; Tibotec-Virco N.V.,
Intellectual Property Department, Generaal De Wittelaan
L11B3, B-2800 Mechelen (BE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR). OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
13 June 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ESTABLISHMENT OF BIOLOGICAL CUT-OFF VALUES FOR PREDICTING RESISTANCE TO THERAPY

(57) Abstract: The present invention concerns methods and systems for improving the accuracy of predicting resistance of a disease to a therapy. In one embodiment of the invention, mean and standard deviation (SD) values of fold change in normalized sensitivity, relative to a laboratory wild type standard pathogen or malignant cell are calculated to demonstrate that the patient samples display inherently different degrees of variation in susceptibility to each therapy. In another embodiment, the 2xSD value for each therapy is used as the cut-off between sensitive (within normal susceptible range) and resistant (above normal susceptible range).

WO 02/33402 A3

INTERNATIONAL SEARCH REPORT

In ternational Application No

PCT/EP 01/12337

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 27480 A (HERTOGS KURT ;PAUWELS RUDI (BE); VIRCO NV (BE); BETHUNE MARIE P DE) 31 July 1997 (1997-07-31) page 7; claim 25; examples 6-12 page 20	1-23
X	RUEBSAMEN-WAIGMANN H ET AL: "RESISTANCE MUTATIONS SELECTED IN VIVO UNDER THERAPY WITH ANTI-HIV DRUG HBY 097 DIFFER FROM RESISTANCE PATTERN SELECTED IN VITRO" ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, vol. 42, May 1999 (1999-05), pages 15-24, XP000885667 ISSN: 0166-3542 page 16 page 22	1-23
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

5 April 2002

Date of mailing of the international search report

12/04/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cuendet, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/12337

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 27319 A (VIROLOGIC INC) 31 July 1997 (1997-07-31) page 13; claim 75 page 69 -----	1-23
X	US 6 103 462 A (CHARNEAU PIERRE ET AL) 15 August 2000 (2000-08-15) column 2 column 4 column 8; claim 1; example 4 -----	1-23
P,X	WO 00 73511 A (PAUWELS RUDI WILFRIED JAN ;HERTOGS KURT (BE); VIRCO NV (BE); LARDE) 7 December 2000 (2000-12-07) page 10 page 21 -page 22; claim 7 -----	1-23

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/12337

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9727480	A	31-07-1997	AU 717755 B2	30-03-2000
			AU 1316897 A	20-08-1997
			BG 102710 A	31-03-1999
			BR 9707204 A	28-12-1999
			CN 1209875 A	03-03-1999
			CZ 9802335 A3	16-06-1999
			EP 0877937 A1	18-11-1998
			WO 9727480 A1	31-07-1997
			NO 983300 A	25-09-1998
			NZ 325912 A	28-01-1999
			PL 328069 A1	04-01-1999
			SK 100298 A3	11-02-1999
			TR 9801443 T2	21-10-1998
			US 6221578 B1	24-04-2001
			ZA 9700669 A	25-06-1998
WO 9727319	A	31-07-1997	AU 732255 B2	12-04-2001
			AU 1952897 A	20-08-1997
			CA 2216126 A1	31-07-1997
			CN 1213407 A	07-04-1999
			EP 1170380 A2	09-01-2002
			EP 0852626 A1	15-07-1998
			HU 9900388 A2	28-05-1999
			JP 2000503849 T	04-04-2000
			NO 983421 A	25-09-1998
			PL 328068 A1	04-01-1999
			WO 9727319 A1	31-07-1997
US 6103462	A	15-08-2000	NONE	
WO 0073511	A	07-12-2000	AU 5217500 A	18-12-2000
			BR 0011555 A	26-02-2002
			WO 0073511 A1	07-12-2000
			EP 1185712 A1	13-03-2002